Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with bladder cancer (a specific type called urothelial carcinoma, including mixed types) that has been confirmed by a pathology test, at certain stages of the disease
- You are 18 years of age or older at the time of signing the consent form
- You are generally able to carry out basic daily activities — even if you use a wheelchair, you may still qualify (confirm with trial site)
- Your blood test results meet certain minimum levels for red blood cells, platelets, white blood cells, and kidney function (confirm with trial site)
- You are willing and able to use highly effective birth control starting from screening, throughout the study, and for at least 6 months after radiation is completed (applies to both men and women)
- Your doctors consider you a suitable candidate for direct treatment of the active cancer with radiation therapy
Who may not be able to join:
- You have an active autoimmune or rheumatologic condition (such as scleroderma, lupus, or ulcerative colitis) that your radiation doctor feels makes radiation therapy unsafe
- You have a psychiatric condition or substance use disorder that your doctor believes would make it difficult to take part in the trial
- Your cancer has spread to distant parts of the body (beyond nearby lymph nodes) in a way that cannot be fully targeted with radiation, in your doctor's opinion
- You have previously had radiation therapy to the pelvic area
- You are still experiencing significant side effects (Grade 2 or higher, except hair loss) from a previous cancer treatment
- You have had poorly controlled diabetes in the last 3 months, based on a specific blood sugar marker being too high and/or related symptoms (confirm with trial site)
- Your doctors estimate your life expectancy is less than 12 weeks
- You already have moderate or severe nerve damage causing numbness, tingling, or weakness (Grade 2 or higher)
- You are currently receiving intravenous (IV) antibiotics or antifungal/antiviral medications for an active infection at the time of joining the trial
- You have a known history of active Hepatitis B or Hepatitis C infection
- You have a known history of HIV infection
- You need to take high doses of steroid medications (more than 10 mg per day of prednisone or equivalent) or other medications that suppress the immune system — note that inhaled or topical steroids and low replacement doses may be allowed (confirm with trial site)
- You have a history of certain lung conditions, such as pulmonary fibrosis or drug-related lung inflammation, or signs of active lung inflammation on a recent chest scan
- You have previously received a bone marrow (stem cell) transplant from a donor or a solid organ transplant (such as a kidney or liver)
- You have active tuberculosis
- You are pregnant, breastfeeding, or planning to become pregnant during the trial period — women who could become pregnant will need a negative pregnancy test before starting radiation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Comron Hassanzadeh, MD, M.D. Anderson Cancer Center
Phone: (713) 657-9802
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.